COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name

joint inv sought o	ventor (if plural names are list on the invention entitled SUS	ted below) of the subje	(if only one name is listed beloest matter which is claimed an HYDROCORTISONE IREA.	d for which a natent is
	is attached hereto			
	was filed onas United States Patent Application No			
\boxtimes	was described and claimed in PCT International Application No. <u>PCI/GB2004/005418</u> , filed on 30 December 2004, and as amended under PCT Articles 19 on (if applicable).			
	and was amended on (if applicable).			
	with amendments through (if applicable)			
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above				
disclose	If this is a continuation-in-pass claims and subject matter in edge the duty to disclose matter in the disclose matter in the prior application and	art application filed un n addition to that disc aterial information as o	thich is material to patentability der the conditions specified in losed in the prior copending aplefined in 37 C.F.R. § 1.56 wh international filing date of the	35 U.S.C § 120 which oplication, I further ich occurred between the
I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the applications(s) on which priority is claimed:				
	Number 0400031.1	Country	Day/Month/Year Filed	Claim Priority?
	04000311	Great Britain	03 January 2004	Yes No
I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:				
	Application Number		Filing Date	

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCI international application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCI International application in the manner provided by the first paragraph of I itle 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in I itle 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCI international filing date of this application:

Application Number

Filing Date

Status: patented, pending, abandoned

I hereby appoint the practitioners associated with the customer number provided below to prosecute this application, to file a corresponding international application, and to transact all business in the Patent and Trademark Office connected therewith:

Customer Number 24197

I hereby grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Combined Declaration and Power of Attorney any further information which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for submitting this document

Address all telephone calls to Sheree Lynn Rybak, Ph D. at telephone number (503) 595-5300.

Address all correspondence to the address associated with Customer Number 24197, which address is:

Klarquist Sparkman, LLP 121 S W Salmon Street, Suite 1600 Portland, OR 97204

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of First or Sole Inventor: Richard Ross

Residence: Sheff

Sheffield, Great Britain

Mailing Address:

c/o University of Sheffield

Division of Clinical Sciences, Northern General Hospital

Herries Road Sheffield S5 7AU GREAT BRITAIN

Citizenship: Great Britain

Inventor's Signature

Date 2/6/07